Market Cap 560.70M
Revenue (ttm) 106.47M
Net Income (ttm) 83.23M
EPS (ttm) N/A
PE Ratio 9.27
Forward PE 21.58
Profit Margin 78.17%
Debt to Equity Ratio 0.40
Volume 833,800
Avg Vol 1,168,486
Day's Range N/A - N/A
Shares Out 58.71M
Stochastic %K 1%
Beta 0.91
Analysts Strong Sell
Price Target $23.00

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 321 939 3416
Website: zevra.com
Address:
1180 Celebration Boulevard, Suite 103, Celebration, United States
intowits
intowits Mar. 21 at 8:21 PM
$ZVRA Per Z's website: "The clinical trial intends to enroll 150 COL3A1 positive VEDS patients. 50 patients will receive placebo and 100 patients will receive celiprolol up to 400 mg/day (200mg bid)." (This is where fda's old school, think Frankenstein's Lab, kicks in for the original SPA agreement:) "The trial will conclude when 46 qualifying events (fatal or non-fatal cardiac event such as rupture of dissection, uterine rupture, colon rupture and/or unexplained sudden death) have been reported." Do they really want to do that to 46 peeps? That is some sick, unethical shite!
1 · Reply
intowits
intowits Mar. 21 at 8:02 PM
$ZVRA just saying: The MAA for Miplyffa was filed 7/28/25. 300 days from that date is 5/27/26, the day after Memorial Day (U.S.) holiday. The CHMP meeting dates for June is 6/22-25/26. They post their meeting agenda 1-2 weeks before the meeting. If the robust data causes an earlier CHMP recommendation, the dates in May are 5/18-21/26. Agenda posted by 5/11/26. CHMP recommendation is rreally what we want to hear. The patent extension comments period ends 3/30/26. If no comments, one month later the new date is signed off on in May. Q1 results announced in May. Celiprolol FDA Meeting Type C discussions results announced in April or MAY. Dreaming, fda says we have seen enough. You good. If Z is smart, wait until all of the above is announced by May/June before entertaining any offers. Except for monetizing Olpruva.
0 · Reply
intowits
intowits Mar. 21 at 7:34 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 21 at 6:28 AM
$ZVRA I thought I’d ask the intelligent audience members of this message board, a very telling question. The JPM conference ended on January 15, 2026. That is to say, 60 days have now passed since the end of the conference. The typical timeline for analyst upgrades / price target revisions post-JPM, from financial analysts, is 10–30 days. Within that timeframe, thy typically issue meaningful upgrades or revised price targets, post JPM conference. Now here’s where I am asking you to put on your thinking hats. Zevra reported its first-ever, profitable quarter since 2006. They also reported a blowout of Wall Street expectations, across the board, on almost every denominating factor, and expressed major catalysts on the way. Despite all of that, whatever few analysts did come through, offered reiterations of their previous price predictions, or else pitiful $1.00 upgrades to their previous predictions. Um… okay, yeah. Who else here, smells something rotten in the rigged town of Denmark?
2 · Reply
ZVRA100
ZVRA100 Mar. 21 at 2:32 AM
$ZVRA shitty days since the earnings call, but the gap’s been filled, and Q2 is starting soon. Hopefully tutes make their quarterly decisions soon to add ZVRA.
1 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 20 at 11:18 PM
$ZVRA Will say it again, the geopolitical climate has little, if any, significant relevance to Zevra, which offers Miplyffa, a life-saving drug, where payers are paying no matter what the war does, or doesn’t do, to the broader market. Shorts are taking advantage of the low trading day volume and algorithms are easily being manipulated to the shorts’ advantage, even more, it seems. That said, a potential BO price in a LOI, is the BO price, and whatever happens to the pps in the interim, is all just noise, imo ✌🏻.
2 · Reply
velle
velle Mar. 20 at 10:49 PM
$ZVRA interest align with the 300k option plan for the CFO but this doesn’t scream imminent BO. Far from it
2 · Reply
MikeyNJ
MikeyNJ Mar. 20 at 8:34 PM
$ZVRA The 300,000 shares granted to Justin Renz, CFO, has an exercise price of $9.55/share. I would say out interests are all aligned.
1 · Reply
intowits
intowits Mar. 20 at 8:18 PM
$ZVRA whatever helps the MAA process right now: March 18, 2026 "EMA launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need." "The first tool, the regulatory roadmap and product development tracker, helps chart a medicine’s progress and flag potential issues early, making it easier for developers and EMA to stay aligned throughout development. The second tool, the expedited scientific advice, is a fast‑track route for developers to receive timely and focused regulatory input on focused questions that are critical for the development process. The third tool, the submission readiness meeting, is a dedicated check-in, about a year before submission, where EMA and developers discuss the progress of the programme against the plan and identify any remaining evidence gaps to ensure that a comprehensive data package is available for a thorough evaluation by the CHMP." https://www.ema.europa.eu/en/news/new-prime-tools-accelerate-development-medicines-eu
0 · Reply
MikeyNJ
MikeyNJ Mar. 20 at 7:04 PM
$ZVRA Great place to be in this market!
0 · Reply
Latest News on ZVRA
Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 4 months ago

Zevra Therapeutics, Inc. Announces CFO Transition


Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:43 PM EDT - 7 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript


Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:45 PM EDT - 11 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 1 year ago

Zevra Therapeutics Files Preliminary Proxy


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 1 year ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes


intowits
intowits Mar. 21 at 8:21 PM
$ZVRA Per Z's website: "The clinical trial intends to enroll 150 COL3A1 positive VEDS patients. 50 patients will receive placebo and 100 patients will receive celiprolol up to 400 mg/day (200mg bid)." (This is where fda's old school, think Frankenstein's Lab, kicks in for the original SPA agreement:) "The trial will conclude when 46 qualifying events (fatal or non-fatal cardiac event such as rupture of dissection, uterine rupture, colon rupture and/or unexplained sudden death) have been reported." Do they really want to do that to 46 peeps? That is some sick, unethical shite!
1 · Reply
intowits
intowits Mar. 21 at 8:02 PM
$ZVRA just saying: The MAA for Miplyffa was filed 7/28/25. 300 days from that date is 5/27/26, the day after Memorial Day (U.S.) holiday. The CHMP meeting dates for June is 6/22-25/26. They post their meeting agenda 1-2 weeks before the meeting. If the robust data causes an earlier CHMP recommendation, the dates in May are 5/18-21/26. Agenda posted by 5/11/26. CHMP recommendation is rreally what we want to hear. The patent extension comments period ends 3/30/26. If no comments, one month later the new date is signed off on in May. Q1 results announced in May. Celiprolol FDA Meeting Type C discussions results announced in April or MAY. Dreaming, fda says we have seen enough. You good. If Z is smart, wait until all of the above is announced by May/June before entertaining any offers. Except for monetizing Olpruva.
0 · Reply
intowits
intowits Mar. 21 at 7:34 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 21 at 6:28 AM
$ZVRA I thought I’d ask the intelligent audience members of this message board, a very telling question. The JPM conference ended on January 15, 2026. That is to say, 60 days have now passed since the end of the conference. The typical timeline for analyst upgrades / price target revisions post-JPM, from financial analysts, is 10–30 days. Within that timeframe, thy typically issue meaningful upgrades or revised price targets, post JPM conference. Now here’s where I am asking you to put on your thinking hats. Zevra reported its first-ever, profitable quarter since 2006. They also reported a blowout of Wall Street expectations, across the board, on almost every denominating factor, and expressed major catalysts on the way. Despite all of that, whatever few analysts did come through, offered reiterations of their previous price predictions, or else pitiful $1.00 upgrades to their previous predictions. Um… okay, yeah. Who else here, smells something rotten in the rigged town of Denmark?
2 · Reply
ZVRA100
ZVRA100 Mar. 21 at 2:32 AM
$ZVRA shitty days since the earnings call, but the gap’s been filled, and Q2 is starting soon. Hopefully tutes make their quarterly decisions soon to add ZVRA.
1 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 20 at 11:18 PM
$ZVRA Will say it again, the geopolitical climate has little, if any, significant relevance to Zevra, which offers Miplyffa, a life-saving drug, where payers are paying no matter what the war does, or doesn’t do, to the broader market. Shorts are taking advantage of the low trading day volume and algorithms are easily being manipulated to the shorts’ advantage, even more, it seems. That said, a potential BO price in a LOI, is the BO price, and whatever happens to the pps in the interim, is all just noise, imo ✌🏻.
2 · Reply
velle
velle Mar. 20 at 10:49 PM
$ZVRA interest align with the 300k option plan for the CFO but this doesn’t scream imminent BO. Far from it
2 · Reply
MikeyNJ
MikeyNJ Mar. 20 at 8:34 PM
$ZVRA The 300,000 shares granted to Justin Renz, CFO, has an exercise price of $9.55/share. I would say out interests are all aligned.
1 · Reply
intowits
intowits Mar. 20 at 8:18 PM
$ZVRA whatever helps the MAA process right now: March 18, 2026 "EMA launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need." "The first tool, the regulatory roadmap and product development tracker, helps chart a medicine’s progress and flag potential issues early, making it easier for developers and EMA to stay aligned throughout development. The second tool, the expedited scientific advice, is a fast‑track route for developers to receive timely and focused regulatory input on focused questions that are critical for the development process. The third tool, the submission readiness meeting, is a dedicated check-in, about a year before submission, where EMA and developers discuss the progress of the programme against the plan and identify any remaining evidence gaps to ensure that a comprehensive data package is available for a thorough evaluation by the CHMP." https://www.ema.europa.eu/en/news/new-prime-tools-accelerate-development-medicines-eu
0 · Reply
MikeyNJ
MikeyNJ Mar. 20 at 7:04 PM
$ZVRA Great place to be in this market!
0 · Reply
DarvasBoxing
DarvasBoxing Mar. 20 at 4:42 PM
$ZVRA I do feel for people out here with high averages and high hopes of moon soon. Just for shingles looked up what IBD listing. I had an account and some visibility still and no re up subscription due to their lack of coverage of biotech. Interesting 52 weeks in this stonk.
2 · Reply
HuntingHighAndLow
HuntingHighAndLow Mar. 20 at 4:19 PM
$ZVRA Assigning the SDX-related IP to the Credit Agreement administrator as collateral couldn't have happened without the Zevra BOD voting to approve it, so there wouldn’t be enough in-house influence to mount a disciplinary action against the CEO as the figurehead for this boondoggle.
0 · Reply
intowits
intowits Mar. 20 at 4:10 PM
$ZVRA per AI: "Basedon recent regulatory filings, the earliest the European Medicines Agency is expected to approve the MAA for Miplyffa is mid-2026." "Zevra officially submitted the MAA to the EMA on July 28, 2025." Estimated Timeline for Approval "The EMA's centralized review process typically follows a standard sequence: CHMP Review: Standard review by the CHMP takes approximately 210 days of "active" time." "Clock Stops: This 210-day period is often interrupted by "clock stops" (usually 3 - 6 mos) while the manufacturer answers specific questions, which can push the total review time to over 300 days." "CHMP Opinion: Based on a July 2025 submission, a positive CHMP opinion would likely be issued in early to mid-2026." "Final EC Decision: Once the CHMP issues its opinion, the European Commission typically takes about 67 days to grant final legal approval." (Q3)
2 · Reply
intowits
intowits Mar. 20 at 3:45 PM
$ZVRA "Lachlan Hanbury Brown has given his Buy rating due to a combo of factors, starting with Zevra’s decision to monetize its SDX portfolio, including Azstarys & KP1077, for $50 mil, which he views as roughly in line w/the intrinsic value of the foregone royalty stream while also eliminating the overhang of ongoing litigation. He emphasizes that these divested royalties were not central to the Zevra equity story, as investor focus is instead anchored on the ramp of Miplyffa in the U.S. & forthcoming regulatory milestones for Miplyffa in Euro." "He highlights the co’s full repayment of its $63 million term loan, which leaves Zevra debt‑free &, meaningfully enhances financial flexibility & reduces risk. He points to encouraging early launch metrics for Miplyffa, w/enrollment forms already covering a substantial portion of the diagnosed NPC population & a rising share of newly diagnosed pats, supporting a thesis of durable demand & market expansion that underpins his positive outlook."
0 · Reply
geegor
geegor Mar. 20 at 3:11 PM
$ZVRA Chuck Norris is dead at 86. Just when we most needed him to sort the CEO & board here out. The Commave deal is probably what finished him off.
0 · Reply
SpacemanLoot
SpacemanLoot Mar. 20 at 2:55 PM
0 · Reply
DaveESIX
DaveESIX Mar. 20 at 2:43 PM
$ZVRA i hope Neil or somebody that reports to him follows these boards. It's plain to see the real owners of the company do not approve of his performance. BOD should be acting...but Tamara is just as rotten
1 · Reply
Cube_CH
Cube_CH Mar. 20 at 2:43 PM
0 · Reply
Sabre2222
Sabre2222 Mar. 20 at 2:39 PM
$ZVRA lots of BO talks on this board. Do you really want a buy out when Neil is in charge? based on his willingness to help his buddies, if a buyout does happen Neil will make out huge as will the rest of the board but stockholders will probably only get 25% over share price. If BO is at $10 shareholders will get $12.50
2 · Reply
velle
velle Mar. 20 at 2:22 PM
$ZVRA ok well gap close to 9.12$ then
0 · Reply
Fire7878
Fire7878 Mar. 20 at 2:12 PM
$ZVRA i wonder how these shenangans impacted $AQST ? Do they get 10% of 50m? A pultry sum given the 650m+ valuation. Seems they got screwed out of 10s of millions by Neil's F up as well.
3 · Reply
lance1965
lance1965 Mar. 20 at 1:01 PM
0 · Reply